Cholangitis

Chemomab Therapeutics has aligned with U.S. regulators on several aspects of the late-stage development of nebokitug, its candidate therapy for primary sclerosing cholangitis (PSC),…

People with primary sclerosing cholangitis (PSC) have a six times higher risk of cancer affecting the large intestine or rectum, and that risk remained…

Adding vitamin D to ursodeoxycholic acid (UDCA) treatment is superior to UDCA alone at reducing symptoms, liver damage markers, and liver scarring in previously untreated…

Hepatocellular carcinoma (HCC), the most common type of liver cancer, is relatively rare among people with primary sclerosing cholangitis (PSC) who do not have…

A class of medicines called PPAR agonists that modulate genes involved in inflammation and scarring improve biochemical markers of liver function and ease itching in…

Umecrine Cognition has raised around $2.5 million to support an ongoing Phase 1b/2a clinical trial testing its investigational therapy golexanolone for cognitive problems and…

An imbalance in the blood between long-chain and very long-chain ceramides — fatty molecules that help fine-tune the body’s inflammatory response — may help indicate…

About 40 in every 100,000 U.S. adults have primary biliary cholangitis (PBC), with its frequency, when adjusted to population size, being highest in some…

The European Medicines Agency (EMA) will review an application for linerixibat, an experimental oral therapy for intense itching associated with primary biliary cholangitis (PBC).

Note: This story was updated Aug. 8, 2025, to correct that infectious mononucleosis was linked to a 4.6 times higher risk of future PSC, not  a…